Sunday, November 8, 2026

EUR/JPY Is 1% Up In The Last 21 Sessions

ViaNews Editorial Team

February 26, 2024

EUR/JPY Is 1% Up In The Last 21 Sessions

(VIANEWS) - EUR/JPY (EURJPY) has been up by 1.69% for the last 21 sessions. At 03:08 EST on Monday, 26 February, EUR/JPY (EURJPY) is $162.92.

EUR/JPY's yearly highs and lows, it's 17.309% up from its 52-week low and 0.827% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/JPY's Forex is considered to be oversold (<=20).

News about

  • Eur/usd weekly forecast: speculators should prepare for volatility this week - 25 February 2024. According to DailyForex on Sunday, 25 February, "S produces surprisingly strong economic data which shows the economy is not slowing down, the EUR/USD could easily drop below the 1.08000 level and retest depths. ", "Nervous conditions may be seen on Monday and build into Tuesday, but by Wednesday any semblance of calm trading conditions in the EUR/USD will likely erode. "
  • Eur/usd loses momentum above the 1.0800 mark amid modest rebound of US dollar. According to FXStreet on Monday, 26 February, "The weaker-than-expected data might weigh on the US Dollar and act as a tailwind for the EUR/USD pair. ", "Traders will take cues from the data and find trading opportunities around the EUR/USD pair."
  • Eur/usd price analysis: depreciates to near 1.0820 before the 21-day EMA. According to FXStreet on Monday, 26 February, "A break above this area could lead the EUR/USD pair to retest the previous week's high at 1.0888 followed by the psychological level of 1.0900.", "This lagging indicator suggests a potential transition toward bullish momentum for the EUR/USD pair."

More news about EUR/JPY (EURJPY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com